ChemotherapyFDA-approvedFirst-line

Nab-paclitaxel

How it works

Nab-paclitaxel is a formulation of paclitaxel that is attached to albumin, allowing it to be delivered directly to cancer cells. It works by disrupting the microtubule network in cancer cells, causing cell death.

Cancer types

Pancreatic CancerAll patients

Efficacy

In clinical trials, nab-paclitaxel in combination with gemcitabine improved overall survival in patients with pancreatic cancer, with a median survival of approximately 6.4 months.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

Evidence from research

StudyCancer typeStageEfficacy
Testing a New Treatment for Advanced Pancreatic CancerPancreatic Cancerphase-2Source →
First-line Treatment Study for Metastatic Pancreatic CancerPancreatic Cancerphase-3Source →
Comparing Two Cancer Treatments for Ovarian CancerOvarian CancerobservationalThe frequency of peripheral neuropathy in the nab-paclitaxel cohort (14%) was half that of the paclitaxel cohort (28%).Source →
New Treatment Combination Shows Promise for Ovarian CancerOvarian Cancerphase-2A 1-month improvement in median progression-free survival and overall survival improvement was seen in the combination arm versus single-agent nab-paclitaxel.Source →
Comparing Treatments for Early Recurring Pancreatic CancerPancreatic CancerobservationalThe gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group.Source →
Combining Radiation and Chemotherapy for Pancreatic CancerPancreatic Cancerphase-1The median overall survival was 22.3 months.Source →
Gemcitabine and Nab-paclitaxel Combination Therapy Linked to Lung Disease in Pancreatic Cancer PatientsPancreatic Cancermeta-analysisSource →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.